These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning.
    Author: Yamada K, Furukawa T.
    Journal: Psychopharmacology (Berl); 1980 Jan; 67(1):39-43. PubMed ID: 6768077.
    Abstract:
    A behavioral study was performed in an attempt to understand the neurological mechanism involved in yawning in rats. Intraperitoneal injections of low doses (0.25 mg/kg) of apomorphine, which preferentially activate presynaptic dopamine autoreceptors, elicited yawning. Whereas apomorphine, at a high dose of 2 mg/kg, produces stereotypy which has been thought to be mediated by stimulation of postsynaptic dopamine receptors. The yawning and stereotypy did not occur simultaneously in the rat. The apomorphine-induced yawning was completely inhibited by pretreatment with fluphenazine (9 mg/kg, IM) or scopolamine (0.5 mg/kg IP), but markedly increased by reserpine (5 mg/kg, SC), however it was not affected by methylscopolamine (0.5 mg/kg, IP). Both physostigmine (0.2 mg/kg, IP), an indirect acetylcholine agonist, and pilocarpine (4 mg/kg, IP), a direct acetylcholine agonist, also induced yawning. This was abolished by scopolamine (0.5 mg/kg, IP) and increased by reserpine (5 mg/kg, SC). Fluphenazine (9 mg/kg, IP) did not affect the pilocarpine-induced yawning but increased the physostigmine-induced yawning. The results indicate that apomorphine elicits yawning by stimulating presynaptic dopamine receptors, and that dopaminergic inhibition and cholinergic activation are concomitantly involved in the yawning.
    [Abstract] [Full Text] [Related] [New Search]